Gustaf Ahlén

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

PhD, Senior Scientist
Projektledare i forskargruppen VIVAC (Vaccin och Immunterapi mot Virus och
Cancer)
Medlem i arbetsmiljökommittén ANA Futura
Jag har en magisterexamen i molekylär cellbiologi från Södertörns
Högskola 2003. Min doktorsexamen erhölls från Karolinska Instutitet 2007
då jag arbetade med att utveckla ett behandlande vaccin för kronisk hepatit
C virusinfektion. Efter min doktorsexamen arbetade jag ett par år som post
doc på ett forskningsföretag som utvecklade vaccin adjuvans. Tillbaka på
KI 2009 som forskningsassistent fortsatte jag arbetet med vaccinutveckling
men nu som behandling för kronisk hepatit B virusinfektion. 2015 började
jag på GE Healthcare (numera Cytiva) och jobbade med skalbara
produktionsprocesser för proteiner och cellbaserade vacciner. Sedan 2018 är
jag tillbaka på KI som projektledare i VIVAC forskargruppen.

Forskningsbeskrivning

Min forskning fokuserar på utveckling av vaccin mot Krim Kongo hemorragisk
feber (CCHF), SARS-CoV-2 och hepatit B och D virus.

Artiklar

Article: GUT. 2023;72(6):1186-1195

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections.

Burm R; Maravelia P; Ahlen G; Ciesek S; Caro Perez N; Pasetto A; Urban S; Van Houtte F; Verhoye L; Wedemeyer H; Johansson M; Frelin L; Sällberg M; Meuleman P
Article: MOLECULAR THERAPY. 2023;31(2):387-397

Accelerated DNA vaccine regimen provides protection against Crimean-Congo hemorrhagic fever virus challenge in a macaque model.

Hawman DW; Meade-White K; Leventhal S; Appelberg S; Ahlén G; Nikouyan N; Clancy C; Smith B; Hanley P; Lovaglio J; Mirazimi A; Sällberg M; Feldmann H
Article: EMBO MOLECULAR MEDICINE. 2022;14(10):e15821

A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells.

Appelberg S; Ahlén G; Yan J; Nikouyan N; Weber S; Larsson O; Höglund U; Aleman S; Weber F; Perlhamre E; Apro J; Gidlund E-K; Tuvesson O; Salati S; Cadossi M; Tegel H; Hober S; Frelin L; Mirazimi A; Sällberg M
Article: JOURNAL OF VIROLOGY. 2022;96(3):e0156821-e01521

Nucleoside-Modified mRNA Vaccines Protect IFNAR-/- Mice against Crimean-Congo Hemorrhagic Fever Virus Infection.

Appelberg S; John L; Pardi N; Végvári Á; Bereczky S; Ahlén G; Monteil V; Abdurahman S; Mikaeloff F; Beattie M; Tam Y; Sällberg M; Neogi U; Weissman D; Mirazimi A
Article: NATURE MICROBIOLOGY. 2021;6(2):187-195

A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model.

Hawman DW; Ahlén G; Appelberg KS; Meade-White K; Hanley PW; Scott D; Monteil V; Devignot S; Okumura A; Weber F; Feldmann H; Sällberg M; Mirazimi A
Article: JOURNAL OF INFECTIOUS DISEASES. 2021;223(1):128-138

Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections.

Maravelia P; Frelin L; Ni Y; Caro Pérez N; Ahlén G; Jagya N; Verch G; Verhoye L; Pater L; Johansson M; Pasetto A; Meuleman P; Urban S; Sällberg M
Article: MOLECULAR & CELLULAR PROTEOMICS. 2021;20:100159

Metabolic Perturbation Associated With COVID-19 Disease Severity and SARS-CoV-2 Replication.

Krishnan S; Nordqvist H; Ambikan AT; Gupta S; Sperk M; Svensson-Akusjärvi S; Mikaeloff F; Benfeitas R; Saccon E; Ponnan SM; Rodriguez JE; Nikouyan N; Odeh A; Ahlén G; Asghar M; Sällberg M; Vesterbacka J; Nowak P; Végvári Á; Sönnerborg A; Treutiger CJ; Neogi U
Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2021;10(7):e1306

SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation.

Sandberg JT; Varnaitė R; Christ W; Chen P; Muvva JR; Maleki KT; García M; Dzidic M; Folkesson E; Skagerberg M; Ahlén G; Frelin L; Sällberg M; Eriksson LI; Rooyackers O; Sönnerborg A; Buggert M; Björkström NK; Aleman S; Strålin K; Klingström J; Ljunggren H-G; Blom K; Gredmark-Russ S; Karolinska COVID‐19 Study Group
Article: JOURNAL OF IMMUNOLOGY. 2020;205(9):2437-2446

Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.

Varnaitė R; García M; Glans H; Maleki KT; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren H-G; Ahlén G; Frelin L; Sällberg M; Blom K; Klingström J; Gredmark-Russ S
Article: CURRENT GENE THERAPY. 2018;18(6):366-374

Clinical-Grade Oncolytic Adenovirus Purification Using Polysorbate 20 as an Alternative for Cell Lysis.

Moleirinho MG; Rosa S; Carrondo MJT; Silva RJS; Hagner-McWhirter Å; Ahlén G; Lundgren M; Alves PM; Peixoto C
Article: GUT. 2018;67(8):1525-1535

Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model.

Levander S; Holmström F; Frelin L; Ahlén G; Rupp D; Long G; Bartenschlager R; Sällberg M
Article: VACCINE. 2016;34(25):2821-2833

A non-human hepadnaviral adjuvant for hepatitis C virus-based genetic vaccines.

Levander S; Sällberg M; Ahlén G; Frelin L
Article: SCIENTIFIC REPORTS. 2016;6:24991

Functional differences in hepatitis C virus nonstructural (NS) 3/4A- and 5A-specific T cell responses.

Holmström F; Chen M; Balasiddaiah A; Sällberg M; Ahlén G; Frelin L
Article: METHODS IN MOLECULAR BIOLOGY. 2016;1403:221-244

Methods to Evaluate Novel Hepatitis C Virus Vaccines.

Ahlén G; Frelin L
Article: MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT. 2016;5:16016

A targeted controlled force injection of genetic material in vivo.

Ahlén G; Frelin L; Holmström F; Smetham G; Augustyn S; Sällberg M
Article: MOLECULAR THERAPY. 2015;23(3):578-590

Functional aspects of intrahepatic hepatitis B virus-specific T cells induced by therapeutic DNA vaccination.

Brass A; Frelin L; Milich DR; Sällberg M; Ahlén G
Article: GENE THERAPY. 2014;21(8):739-750

Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination.

Ahlén G; Holmström F; Gibbs A; Alheim M; Frelin L
Article: JOURNAL OF IMMUNOLOGY. 2014;192(4):1671-1680

Cleavage of the T cell protein tyrosine phosphatase by the hepatitis C virus nonstructural 3/4A protease induces a Th1 to Th2 shift reversible by ribavirin therapy.

Brenndörfer ED; Brass A; Karthe J; Ahlén G; Bode JG; Sällberg M
Article: JOURNAL OF INFECTIOUS DISEASES. 2013;208(6):1008-1019

A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus.

Fournillier A; Frelin L; Jacquier E; Ahlén G; Brass A; Gerossier E; Holmström F; Broderick KE; Sardesai NY; Bonnefoy J-Y; Inchauspé G; Sällberg M
Article: MOLECULAR THERAPY. 2013;21(9):1796-1805

Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C.

Weiland O; Ahlén G; Diepolder H; Jung M-C; Levander S; Fons M; Mathiesen I; Sardesai NY; Vahlne A; Frelin L; Sällberg M
Article: ALLERGY. 2013;68(4):549-552

Identification of galactose-α-1,3-galactose in the gastrointestinal tract of the tick Ixodes ricinus; possible relationship with red meat allergy.

Hamsten C; Starkhammar M; Tran TAT; Johansson M; Bengtsson U; Ahlén G; Sällberg M; Grönlund H; van Hage M
Article: JOURNAL OF IMMUNOLOGY. 2013;190(3):1113-1124

A synthetic codon-optimized hepatitis C virus nonstructural 5A DNA vaccine primes polyfunctional CD8+ T cell responses in wild-type and NS5A-transgenic mice.

Holmström F; Pasetto A; Nähr V; Brass A; Kriegs M; Hildt E; Broderick KE; Chen M; Ahlén G; Frelin L
Article: METHODS IN MOLECULAR BIOLOGY. 2013;940:239-267

Methods for monitoring gene gun-induced HBV- and HCV-specific immune responses in mouse models.

Ahlén G; Sällberg M; Frelin L
Article: JOURNAL OF IMMUNOLOGY. 2012;189(9):4510-4519

TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity.

Pasetto A; Frelin L; Aleman S; Holmström F; Brass A; Ahlén G; Brenndörfer ED; Lohmann V; Bartenschlager R; Sällberg M; Bertoletti A; Chen M
Article: JOURNAL OF GENERAL VIROLOGY. 2012;93(Pt 8):1680-1686

Limited effect on NS3-NS4A protein cleavage after alanine substitutions within the immunodominant HLA-A2-restricted epitope of the hepatitis C virus genotype 3a non-structural 3/4A protease.

Ahlén G; Chen A; Roe B; Falkeborn T; Frelin L; Hall WW; Sällberg M; Söderholm J
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2012;44(1):55-59

A bi-functional hepatitis B virus core antigen (HBcAg) chimera activates HBcAg-specific T cells and preS1-specific antibodies.

Malik IR; Chen A; Brass A; Ahlén G; Rahman M; Sällberg M; Qureshi JA; Frelin L
Article: PLOS ONE. 2012;7(10):e46959

Mannosylated mucin-type immunoglobulin fusion proteins enhance antigen-specific antibody and T lymphocyte responses.

Ahlén G; Strindelius L; Johansson T; Nilsson A; Chatzissavidou N; Sjöblom M; Rova U; Holgersson J
Article: JOURNAL OF IMMUNOLOGY. 2011;186(9):5107-5118

Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3/4A-specific T cells during therapeutic vaccination.

Chen A; Ahlén G; Brenndörfer ED; Brass A; Holmström F; Chen M; Söderholm J; Milich DR; Frelin L; Sällberg M
Article: DRUG NEWS AND PERSPECTIVES. 2010;23(10):647-653

Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?

Frelin L; Brass A; Ahlén G; Brenndörfer ED; Chen M; Sällberg M
Article: HEPATOLOGY. 2010;52(5):1553-1563

Anti-tumor necrosis factor α treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C.

Brenndörfer ED; Weiland M; Frelin L; Derk E; Ahlén G; Jiao J; Bode JG; Sällberg M
Article: JOURNAL OF INFECTIOUS DISEASES. 2010;201(12):1867-1879

Improving on the ability of endogenous hepatitis B core antigen to prime cytotoxic T lymphocytes.

Nyström J; Chen A; Frelin L; Ahlén G; Koh S; Brass A; Peterson DL; Fons M; Milich DR; Hultgren C; Sällberg M
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2009;284(41):28343-28351

The hepatitis C virus non-structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo.

Kriegs M; Bürckstümmer T; Himmelsbach K; Bruns M; Frelin L; Ahlén G; Sällberg M; Hildt E
Article: GUT. 2009;58(4):560-569

Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes.

Ahlén G; Derk E; Weiland M; Jiao J; Rahbin N; Aleman S; Peterson DL; Pokrovskaja K; Grandér D; Frelin L; Sällberg M
Article: JOURNAL OF IMMUNOLOGY. 2007;179(7):4741-4753

In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells.

Ahlén G; Söderholm J; Tjelle T; Kjeken R; Frelin L; Höglund U; Blomberg P; Fons M; Mathiesen I; Sällberg M
Article: GUT. 2006;55(10):1475-1483

The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor alpha mediated liver disease.

Frelin L; Brenndörfer ED; Ahlén G; Weiland M; Hultgren C; Alheim M; Glaumann H; Rozell B; Milich DR; Bode JG; Sällberg M
Article: GUT. 2006;55(2):266-274

Relation between viral fitness and immune escape within the hepatitis C virus protease.

Söderholm J; Ahlén G; Kaul A; Frelin L; Alheim M; Barnfield C; Liljeström P; Weiland O; Milich DR; Bartenschlager R; Sällberg M
Article: JOURNAL OF INFECTIOUS DISEASES. 2005;192(12):2112-2116

In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes.

Ahlen G; Nystrom J; Pult I; Frelin L; Hultgren C; Sallberg M
Article: GENE THERAPY. 2004;11(6):522-533

Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene.

Frelin L; Ahlén G; Alheim M; Weiland O; Barnfield C; Liljeström P; Sällberg M
Visa fler

Alla övriga publikationer

Review: IMMUNO-ONCOLOGY AND TECHNOLOGY. 2022;16:100099

ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing.

Silva DN; Chrobok M; Ahlén G; Blomberg P; Sällberg M; Pasetto A
Letter: JOURNAL OF VIROLOGY. 2020;94(18):e01279-e01220

The SARS-CoV-2 N Protein Is a Good Component in a Vaccine.

Ahlén G; Frelin L; Nikouyan N; Weber F; Höglund U; Larsson O; Westman M; Tuvesson O; Gidlund E-K; Cadossi M; Appelberg S; Mirazimi A; Sällberg M; OPENCORONA Consortium
Editorial comment: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2019;50(8):963-964

Editorial: HBV-the naked truth?

Pasetto A; Ahlén G; Sällberg M
Review: MEDICAL MICROBIOLOGY AND IMMUNOLOGY. 2015;204(1):131-135

Electroporation for therapeutic DNA vaccination in patients.

Sällberg M; Frelin L; Ahlén G; Sällberg-Chen M
Review: DRUG RESISTANCE UPDATES. 2013;16(3-5):60-67

Containing "The Great Houdini" of viruses: combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C.

Ahlén G; Frelin L; Brenndörfer ED; Brass A; Weiland O; Chen M; Sällberg M
Meeting abstract: JOURNAL OF HEPATOLOGY. 2010;52:S239

IMPROVING ON THE ABILITY OF ENDOGENOUS HEPATITIS B CORE ANTIGEN TO PRIME CYTOTOXIC T LYMPHOCYTES

Chen A; Nystrom J; Frelin L; Ahlen G; Koh S; Peterson DL; Fons M; Milich D; Hultgren C; Sallberg M
Meeting abstract: JOURNAL OF HEPATOLOGY. 2009;50:S47

COMBINATION THERAPY WITH THERAPEUTIC VACCINATION AND INHIBITION OF PD-L1 IMPROVES T CELL FUNCTION IN HCV-TRANSGENIC MICE

Frelin L; Brenndorfer ED; Ahlen G; Chen A; Tjelle T; Kjeken R; Fons M; Mathiesen I; Sallberg M

Anställningar

Projektledare, Laboratoriemedicin, Karolinska Institutet, 2018-

Examina och utbildning

MEDICINE DOKTORSEXAMEN, Institutionen för laboratoriemedicin, Karolinska Institutet, 2007

Om mig

Forskningsbeskrivning

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI